The National Institute for Health and Care Excellence and the Canadian Agency for Drugs and Technology in Health are to work together to help life science companies prepare for future health technology assessments by answering their questions and providing key insight on their clinical and health economic development plans. They will also help companies to develop evidence that demonstrates the value of a technology by providing detailed feedback on their clinical and economic evidence generation plans, using expert opinion from a range of contributors including clinicians, health economists and patient representatives. Within the advice service there will be a joint summary, highlighting areas of collaboration from the two agencies, and two separate advice reports from NICE and CADTH.
“NICE and CADTH to collaborate on scientific advice to life sciences industry.“
Director of NICE Scientific Advice, Jeanette Kusel, said: “We recognise the inherent difficulties faced by developers in designing clinical trial programmes that meet the precise requirements of multiple international markets. This new collaboration with CADTH uses the synergies between the English and Canadian systems and provides companies with comprehensive and practical advice from both countries through a single, streamlined process.”